Comparison of Two Methods in the Treatment of Cytomegalovirus of the Eyes in Patients With AIDS
Completed · Phase 2
Conditions studied: Cytomegalovirus Retinitis, HIV Infections
In brief
To evaluate the effect of MSL 109, human monoclonal anti-cytomegalovirus (CMV) antibody, on time to progression of CMV retinitis. To determine the safety and pharmacokinetic profile of MS 109. To evaluate the relationship between pharmacokinetic measurements of MSL 109 and efficacy and virologic markers. Therapeutic agents currently available for CMV retinitis are limited by their inherent toxicities and short half-lives which require frequent intravenous dosing. Alternatively, MSL 109 has demonstrated safety and effectiveness in neutralizing CMV isolates at concentrations easily maintained in AIDS patients.
Key facts
- Study ID
- NCT00001061
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
- People needed
- 167
- Expected to finish
- 1998-03-01
- Last updated by the study team
- 2021-11-01
Who can join
Age: 13 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Concurrent Medication:
- Allowed:
- G-CSF and GM-CSF.
- Antiretroviral therapy.
- Patients must have:
- HIV infection.
- First episode of CMV retinitis.
- No prior end-organ CMV disease - PER AMENDMENT 4/25/96: No prior end organ CMV disease within the past 6 months. Subjects who have been prophylaxed with oral ganciclovir and develop an episode of CMV retinitis are eligible.
- No active AIDS-defining opportunistic infection or malignancy that requires nephrotoxic or myelosuppressive therapy.
- Life expectancy of at least 6 months.
- Consent of parent or guardian if less than 18 years of age.
- NOTE:
- This protocol is approved for prisoner participation.
You may not qualify if…
- Co-existing Condition:
- Patients with the following symptoms or conditions are excluded:
- PER AMENDMENT 4/25/96: Retinal detachment not scheduled for surgical repair, in all eyes meeting other eligibility criteria. (Was written as - No current retinal detachment (although old retinal detachments unrelated to HIV infection which have been repaired are permitted).
- Corneal, lens, or vitreous opacification that precludes funduscopic exam.
- Clinically significant pulmonary or neurologic impairment, such as intubation or coma. (Patients with a CNS mass or history of seizure disorder may enroll.)
- Tuberculous, diabetic, or hypertensive retinopathy, or other retinal lesions that would interfere with measurements of response or progression.
- Known hypersensitivity to the study drugs.
- PER AMENDMENT 4/25/96:
- Presence of CMV retinal lesions that are only in areas of the retina which cannot be photographed.
- Concurrent Medication:
- Excluded:
- Immunomodulators, biologic response modifiers, interferon, or investigational agents that may influence course of CMV infection.
- Systemic acyclovir or any nephrotoxic agent, specifically aminoglycosides, amphotericin B, and parenteral pentamidines.
- Any concomitant therapy that would preclude use of cidofovir, foscarnet or ganciclovir.
- Prior Medication:
- Excluded: PER AMENDMENT 4/25/96:
- Use of IV ganciclovir, foscarnet or cidofovir within 6 months prior to study enrollment. (Was written - Ganciclovir or foscarnet for non-CMV herpes infections within 6 months prior to study entry.)
Where it is running
- Alabama Therapeutics CRS — Birmingham, Alabama, United States
- USC CRS — Los Angeles, California, United States
- Santa Clara Valley Med. Ctr. — San Jose, California, United States
- Stanford CRS — Stanford, California, United States
- University of Colorado Hospital CRS — Aurora, Colorado, United States
- Univ. of Miami AIDS CRS — Miami, Florida, United States
- Queens Med. Ctr. — Honolulu, Hawaii, United States
- Univ. of Hawaii at Manoa, Leahi Hosp. — Honolulu, Hawaii, United States
- Cook County Hosp. CORE Ctr. — Chicago, Illinois, United States
- Rush Univ. Med. Ctr. ACTG CRS — Chicago, Illinois, United States
- Indiana Univ. School of Medicine, Infectious Disease Research Clinic — Indianapolis, Indiana, United States
- Massachusetts General Hospital ACTG CRS — Boston, Massachusetts, United States
- Beth Israel Deaconess - East Campus A0102 CRS — Boston, Massachusetts, United States
- Beth Israel Deaconess Med. Ctr., ACTG CRS — Boston, Massachusetts, United States
- Washington U CRS — St Louis, Missouri, United States
- SUNY - Buffalo, Erie County Medical Ctr. — Buffalo, New York, United States
- Univ. of Rochester ACTG CRS — Rochester, New York, United States
- Univ. of Cincinnati CRS — Cincinnati, Ohio, United States
- Case CRS — Cleveland, Ohio, United States
- Hosp. of the Univ. of Pennsylvania CRS — Philadelphia, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.